Homocystinuria is a rare inborn error of methionine metabolism caused by cystathionine -synthase (CBS) deficiency. The prevalence of homocystinuria in Qatar is 1:1,800 births, mainly due to a founder Qatari missense mutation, c.1006C>T; p.R336C (p.Arg336Cys). We characterized the structure-function relationship of the p.R336C-mutant protein and investigated the effect of different chemical chaperones to restore p.R336C-CBS activity using three models: in silico, ΔCBS yeast, and CRISPR/Cas9 p.R336C knock-in HEK293T and HepG2 cell lines. Protein modeling suggested that the p.R336C induces severe conformational and structural changes, perhaps influencing CBS activity. Wild-type CBS, but not the p.R336C mutant, was able to restore the yeast growth in ΔCBS-deficient yeast in a complementation assay. The p.R336C knock-in HEK293T and HepG2 cells decreased the level of CBS expression and reduced its structural stability; however, treatment of the p.R336C knock-in HEK293T cells with betaine, a chemical chaperone, restored the stability and tetrameric conformation of CBS, but not its activity. Collectively, these results indicate that the p.R336C mutation has a deleterious effect on CBS structure, stability, and activity, and using the chemical chaperones approach for treatment could be ineffective in restoring p.R336C CBS activity.
INTRODUCTION
Homocystinuria is a rare metabolic disease caused by cystathionine beta synthase (CBS) deficiency (MIM# 236200), which is characterized by high homocysteine (Hcy) and methionine levels in blood and urine. Catastrophic mutations in CBS are considered the main cause of homocystinuria, and an elevation of Hcy in urine can be the first sign for the diagnosis of homocystinuria (Mudd, Finkelstein, Irreverre, & Laster, 1964; Mudd et al., 1985) . Qatar has the highest prevalence of homocystinuria in the world (1:1,800 births), making homocystinuria the most prevalent inherited monogenic disease in Qatar (Zschocke et al., 2009 ). The high prevalence in Qatar is attributed to the founder mutation c.1006C>T; p.R336C (p.Arg336Cys; El-Said et al., 2006) . Molecular genetic analyses have so far identified more than 150 different pathogenic mutations in CBS (http://cbs.lf1.cuni.cz/mutations. php). Human CBS is 63 kDa in size and resides in the cytosol as a homotetramer. CBS has three functional domains: (i) an N-terminal domain that binds heme, which was shown to be essential for the redox-linked regulation of CBS, (ii) a central catalytic core that binds a cofactor called pyridoxal 5-phosphate (PLP), and (iii) a C-terminal domain that binds the allosteric effector S-adenosylmethionine (AdoMet; Ereno-Orbea, Majtan, Oyenarte, Kraus, & Martinez-Cruz, 2014) . Hcy is an intermediary amino acid that is metabolized by two different pathways. It can be either remethylated to form methionine or condensed with serine and enter the transsulfuration pathway. CBS is the first enzyme in the transsulfuration pathway, catalyzing the condensation of Hcy with serine to form cystathionine, which can then be cleaved to form cysteine. The CBS-mediated reaction requires pyridoxine as a cofactor (reviewed in Škovierová et al., 2016) .
It is thought that the Qatari homozygous mutation renders CBS inactive. Due to CBS inactivity, Hcy accumulates, leading to homocystinuria, hypocysteinemia, and hypermethioninemia. The accumulation of Hcy in blood is strongly linked to the development of serious conditions, including cardiovascular and neurodegenerative diseases.
Untreated Qatari patients usually undergo severe complications such as mental retardation, physical deformation, and death. Qatari homocystinuric patients do not respond to high doses of pyridoxine (El-Said et al., 2006; Zschocke et al., 2009) . Current therapeutic approaches for Qatari patients include life-long methionine-restricted diet and cysteine supplements. However, these therapeutic approaches are not optimal, as dietary compliance can be very difficult. Consequently, there is a huge clinical, financial, and psychosocial burden requiring to develop more efficient therapeutic approaches specific for this mutation (El-Said et al., 2006; Gan-Schreier et al., 2010; Schiff & Blom, 2012; Zschocke et al., 2009 ).
Rather than focusing on repairing the mutation at the DNA level, which is still a challenge, research is focused on correcting the mutation at the protein level, and hence, restoring CBS enzymatic activity.
Recent studies suggest that chemical chaperon (low-molecular-weight molecules) therapies are an emerging novel concept for protein misfolding diseases (Suzuki, 2014) . Different types of chemical chaperones were shown to restore the folding errors in mutated CBS proteins (Kopecka, Krijt, Rakova, & Kozich, 2011; Singh, Chen, Kozich, & Kruger, 2007; Suzuki, 2014) . However, the effect of these chemical chaperons on the p.R336C mutation and the exact mechanism of action needs further investigation. In this study, we hypothesized that chemical chaperones may restore the activity and functionality of the CBS-p.R336C mutant. To achieve this, we generated and validated three models: (i) in silico, where protein modeling and simulations were performed to study the mutational consequences at the molecular level, (ii) yeast model (Saccharomyces cerevisiae), and (iii) cell culture models involving knocking-in the mutant CBS in HEK293T and HepG2 cell lines. After successful validation, these models were used to assess the effect of the p.R336C mutation on CBS expression, stability, and activity, as well as the ability of different chemical chaperones to restore CBS expression and activity.
MATERIALS AND METHODS
Chemicals and reagents were purchased from Sigma-Aldrich (GmBH, Germany) unless otherwise stated. These chemicals were used directly without further modifications.
Molecular modeling

Structural loop repair
From the protein data bank (PDB# P35520), we have used the full structure of human CBS (hCBS) domain (missing loop region [515] [516] [517] [518] [519] [520] [521] [522] [523] [524] [525] [526] [527] with the best possible high resolution at 2Å (McCorvie et al., 2014) for molecular modeling. This structure has been used in discovery studio (DS; Accelrys Inc., San Diego, CA, USA) to model/repair the loop region, in which we used potential structural alignments of the missing residues. The repaired structure was further used in docking for original positioning of the heteroatoms heme and pyridoxal 5 ′ -phosphate.
The resultant structure is considered as wild-type of hCBS, and this is used to create a mutant protein model (p.R336C) as described previously (Gajendrarao et al., 2013; Krishnamoorthy, Yacoub, & Yaliraki, 2011 ).
Molecular dynamics simulations
The hCBS and p.R336C were used in the GROMACS simulations package for the molecular dynamics (MD) simulations. The heteroatoms and the amino acids were prepared for the simulations by applying GROMOS96 force field (Hess, Kutzner, van der Spoel, & Lindahl, 2008; Van Der Spoel et al., 2005; Van Gunsteren, 1996) . The water model of SPC3 was used for solvation of the proteins in a cubic box with a size of 1.5 nm. In order to neutralize the systems, the counter ions were added, and the periodic boundary conditions were applied in all directions. The resulting systems consist of 141,443 atoms to 141,452 atoms. For handling the long-range interactions, a twin range cutoff was used: 0.8 nm for van der Walls and 1.4 nm for electrostatic interactions. The SETTLE algorithm (Miyamoto & Kollman, 1992 ) was applied to constrain the geometry of the water molecules, while the LINCS algorithm (Hess, Bekker, Berendsen, & Fraaijey, 1997) was utilized to constrain all the bond lengths. The systems were energy minimized by applying steepest descent algorithm with a tolerance of 2,000 Kj/mol/nm. The resultant structures were preequilibrated with 100 ps simulation prior to producing MD simulation of 25 ns with a time step of 2 fs at constant temperature (300 K), pressure (1 atm), and number of particles, without any position restraints. At every 100 ps, a coordinate file was obtained and the tools of PyMOL, DS, and GRO-MACS were used to analyze changes in structure, stability, and molecular interactions.
Cluster analysis and surface map
To select the representative structure from MD simulations, the collected structures of 2,500 from MD simulations were all grouped into clusters according to their structural deviations. The top-ranked cluster was selected for representation as it is a frequently occurring conformation. These representative structures were used in surface mapping analysis in DS to identify changes in the binding cavities and surface conformations.
Yeast model generation
The wild-type human CBS cDNA (sequence reference NM_ 001178008.2), the CBS c.1006C>T and c.833T>C mutant sequences were PCR amplified from pLW2:hCBS, pLW2:R336C, and pLW:I278T, respectively (Wang et al., 2004) . The PCR-amplified cDNA fragments were cloned into a gap repair yeast cloning and expression plasmid pYEPGAPx:ΔhCBS, and were transformed into the S. cerevisiae ΔCBS yeast strain, WY35 (WY35ΔyCBS), by lithium acetate cotransformation as described in Shan, Dunbrack, Christopher, and Kruger (2001) . 
2.3.2
Assessment of CBS mutation efficiency Figure S1 ).
For simplicity, the CRISPR-CAS p.R336C knock-in HEK293T cells were designated as p.R336C-HEK, while the CRISPRCAS p.R336C
knock-in HepG2 cells were designated as p.R336C-HepG2. The wildtype cells for both cell lines were designated as wt-HEK and wt-HepG2.
Assessment of CBS mRNA expression
RNA extraction from cells was performed from 70% cell confluent 6-well plates using TRIzol. 
Cell viability and growth curve experiments
Two different models were used in this study: the yeast model and the cell culture model with two cell lines (HEK293T and HepG2). For yeast, we followed the same protocols as described in Kruger and Cox (1995) . Briefly, yeast cells from a saturated synthetic complete (SC-trp, 
Chemical chaperone treatment
HEK293T cells were treated with four chemical chaperons (sorbitol, proline, betaine, and glycerol). Briefly, cells were cultured in 6-well plates in complete media (DMEM supplemented with 10% FBS, 1%
antibiotics, and 1% L-glutamine) and incubated for 16-18 h at humidified conditions (37 • C, 5% CO 2 ). Cells were then treated with different concentrations of the chemical chaperones; 48 h after treatment, cells were lysed using RIPA buffer (Thermo Fisher) supplemented with a protease inhibitor cocktail (Thermo Fisher). Cell lysates were collected and centrifuged at 15,000 RPM for 15 min to be used for protein analysis. Protein concentration from both models was determined using BCA assay (Pierce) using bovine serum albumin as a standard. CBS expression and conformation were assessed by western blot analysis.
Gel electrophoresis, western blotting, and CBS activity
To assess CBS expression in yeast, protein was extracted by a modified post-alkaline extraction procedure as previously described (Kushnirov, 2000) . To assess the protein conformation, yeast extracts were prepared via mechanical lysis by sonication for 10 sec followed by 1 min on ice for four cycles at 100% amplitude (Liu, Zeng, Sun, & Han, 2013) .
Extracts containing 48 g of total protein were separated on 10%
native and denatured PAGE as described by Singh and Kruger (2009) .
Protein expression and conformation were assessed in the mammalian cell culture model using the same standard procedure. Protein was transferred onto a polyvinylidene difluoride (PVDF) membrane (Invitrolon, Novex, Life Technologies) that were probed with immunopurified mouse anti-CBS pAb (Abnova) at a 1/1,000 dilution followed by a 1/5,000 dilution of goat antimouse IgG (H&L) secondary antibody (Abnova). Probed membranes were subjected to enhanced chemiluminescence reagent (ECL, Abcam).
CBS activity was determined using Biochrom 30+ Amino Acid
Analyzer as previously described (Wang, Li, Cho, & Malik, 2014) 
Statistical analysis
Data were represented as mean ±SD and statistical significance (taken as *P < 0.05) was determined using GraphPad Prism 5. The specific statistical test used in each experiment is mentioned in the figure legends.
RESULTS
In silico protein modeling and simulations
The modeled loop in hCBS revealed the structure and conformation of the loop region 515-527. This loop plays a key role in the substrate binding mechanism that was recently reported (McCorvie et al., 2014 ; Figure 1A ). The modeling of hCBS showed the importance of the location of residue Arg336, which is close to the catalytic core region. The simulation of hCBS described the stable nature of the wild-type. In contrast, the p.R336C mutation induced a large conformational shift in the secondary structural elements, which affects the functional core region ( Figure 1C ). These changes reduced the conformational stability of p.R336C ( Figure 1B ,a) and led to conformational changes ( Figure 1C) . As a result, the regular intramolecular hydrogen bonds are increased ( Figure 1B,b) . The Arg residue is at position 336 of wt-hCBS and contributes to the local stability by forming three hydrogen bonds, on average, during the simulation ( Figure 1B,c) . However, in the p.R336C mutant, the Cys residue at 336 was unable to maintain the local network and stability compared with hCBS. The above changes at the integral part of the mutant bring a significant transformation to the surface with an enlargement in the near field of the mutational spot that appears like a cavity ( Figure 1D ). This modeling Statistical analysis for the effect between different strains was measured by two-way ANOVA followed by Bonferroni post-hoc test (*P < 0.05) provides a molecular basis of the mutation that could affect the function by introducing conformational changes due to the modification in the number of hydrogen bonds and the surface. However, structurefunctional relationships were further studied in detail to correlate the structural changes with the phenotype using in vitro and in vivo experimental analyses.
p.R336C failed to restore the growth defect in the CBS-deficient yeast ( CBS)
We used the previously established yeast model by Kruger and Cox (1994) to study the ability of pLR336C plasmid to restore the growth defect of ΔCBS, as indirect assessment of p.R336C enzyme activity in vivo. As shown in Figure 2A , all yeast strains were able to grow in the presence of cysteine. However, only the yeast strain carrying pLhCBS plasmid was able to grow on media lacking cysteine, while the strains carrying the pLI278T, the pLΔhCBS, and the pLR336C-mutant plasmid failed to grow. The p.I278T is another deleterious CBS mutation, in which isoleucine is replaced by threonine at position 278 (Kruger & Cox, 1994 , 1995 , and was used as a control. These results suggested that the p.R336C mutation is lethal in yeast, and exogenous cysteine is essential to maintain growth due to the malfunctioning CBS activity.
p.R336C mutation affects the level of CBS expression and activity in yeast
Western blot analysis of the four yeast strains under both denaturing and native conditions was performed. As shown in Figure 2B , steady-state levels of CBS in the pLR336C-mutant yeast strain were lower than those in the pLhCBS strain. However, pLR336C expressed higher level of CBS protein compared with the mutant strain carrying the p.I278T mutant, which is known to affect protein stability (Singh & Kruger, 2009 ). Similar to hCBS, p.R336C protein seems to form a tetramer as assessed by native gel electrophoresis ( Figure 2B ). Whether such bands represent a functional or nonfunctional tetrameric CBS protein, our results indicate that the p.R336C mutation renders CBS nonfunctional. That is, CBS activity in the wholecell lysates of the pLR336C strain was lower than the detection limit 
CBS expression and activity in HEK293T and HepG2 cells
We used CRISPR/Cas9 knock-in technology to create p.R336C CBS mutation in HEK293T kidney and HepG2 liver cells (Supporting Information Figure S1 ). Due to the nature of disease pathology, we initially chose HepG2 cells as CBS is known to be expressed at a high level in the liver cells. However, at first, we failed to transfect HepG2 cells with the Cas9 plasmid. In fact, the resistance of HepG2 cells for transfection is also reported in the literature (Das et al., 2016) . Thus, as a proof of concept, we decided to use, in parallel, a well-adapted laboratory cell line (HEK293T cells) that is relatively easy to transfect and capable of expressing sufficient amounts of CBS, which is well expressed in the kidney. In human and mouse, it is known that CBS is expressed predominantly in liver, pancreas, kidney, and brain (reviewed in Kruger, 2017) .
As shown in Figure 3A and 3B, wt-HEK293T cells express high levels of CBS mRNA and protein, making them suitable for our study. Surprisingly, it turned out that wt-HEK293T was a better cell line to study CBS protein than HepG2 cells as the former cells showed a better CBS protein expression level and activity (501.1 mU/mg/h) than the wt-HepG2 cells (9.8 mU/mg/h; Figure 3B ).
p.R336C mutation affects CBS mRNA expression, structure, and activity in mammalian cells
To study the effect of c.1006C>T mutation (p.R336C) on CBS gene expression, the level of mRNA expression in both wild-type and mutant HEK293T and HepG2 cells was measured in relation to GAPDH mRNA levels ( Figure 3A ). There was no significant difference in the mRNA expression level of CBS between the wt-HEK and the p.R336C-HEK cells. However, in HepG2 cells, c.1006C>T mutation significantly decreased the mRNA expression level of CBS.
Next, we examined the effect of p.R336C mutation on CBS protein level in both cell lines by denatured western blot analysis.
CBS protein expression (as a monomer) was significantly lower in F I G U R E 4 Restoring CBS protein conformation in p.R336C-HEK cells by treatments with different chemical chaperons. Cell lysates were prepared and examined for CBS conformation using 10% native PAGE gels followed by immunoblotting. Protein sample (40 g) was loaded per lane. This experiment was repeated three times and similar results were obtained. CBS activity was measured as described in the "Materials and Methods" section. CBS activity in sorbitol-, proline-, and glycerol-treated HEK293 was not assessed as these chaperones did not restore the tetrameric conformation of CBS p.R336C-HEK cells compared with wt-HEK cells ( Figure 3B and 3C) .
Notably, CBS monomer was not detected in p.R336C-HepG2 cells compared with wt-HepG2 cells, suggesting that p.R336C mutation has a dramatic effect on CBS protein expression level in both cell lines. Furthermore, the native gel showed the presence of the CBS tetrameric active conformation in wt-HEK cells, which was absent in p.R336C-HEK cells ( Figure 3D ). These findings were congruent with the CBS activity results, in which CBS activity was below detection limit (<5 mU/mg/h) in p.R336C-HEK and p.R336C-HepG2 cells compared to wt-HEK and wt-HepG2 cells (501.1 and 9.8 mU/mg/h, respectively; Figure 3B ). These results suggest that p.R336C mutation leads to significant destabilization of CBS in mammalian cells.
Betaine restores CBS conformation, but not activity, in HEK293T cells
Because were capable of retrieving CBS protein in the p.R336C-HEK cells (Figure 4 ). Yet, the retrieved CBS protein did not always have the right tetrameric conformation. Although sorbitol, proline, and glycerol protected CBS from degradation, they were unable to restore the active tetrameric conformation. Hence, CBS activity was not assessed in p.R336C-HEK cells after treatment with sorbitol, proline, and glycerol.
Interestingly, betaine not only protected the CBS protein from undergoing degradation, but also restored the tetrameric conformation (Figure 4) . Surprisingly, however, CBS activity was below the detection limit (<5.0 mU/mg/h) in betaine-treated p.R336C-HEK cells. These results indicate that betaine can reestablish the tetrameric conformation of p.R336C CBS, but not its activity, in HEK293T cells.
DISCUSSION
One of the most severe homocystinuria phenotypes is due to the p.R336C mutation, which was shown to be nonresponsive to the pharmaceutical therapeutic approaches. Therefore, therapy in patients harboring this mutation is based on a low methionine diet.
Little is known about this mutant in terms of structural conformation, in vitro, and in vivo responses to different treatments. Clinically, supplementation with high dose of pyridoxine (vitamin B6) was shown to lower the plasma level of Hcy in patients with the p.I278T (Kluijtmans et al., 1999; Kraus et al., 1999) , but not the p.R336C
mutation (El-Said et al., 2006) , hence the need for additional strategies to lower plasma Hcy in patients harboring the p.R336C mutation.
Here, we used the previously characterized CBS mutation, p.I278T, as a negative control for the yeast growth and rescue experiments (Figure 2 ).
We constructed an in silico model that revealed the structural and conformational differences between hCBS and its p.R336C mutant (Figure 1 ). The p.R336C mutation causes severe secondary structural changes to the functional core region. The near field of the mutational spot on the surface is modified and looks like a cavity (Figure 1 ). This cavity might provide a binding site for a single or multiple substrates.
It is possible that this cavity exhibits a new access route for the substrates to the functional core, which seems to be different from a previous report (McCorvie et al., 2014) . However, further studies with target substrates are needed to understand the entry/exit mechanism in order to design selective drugs that could retrieve CBS function.
Our in silico model shows that p.R336C is also a buried mutation that confers lower structural stability compared with the hCBS. These similarities between the p.R336C and the p.I278T mutants explain the reason of using p.I278T as a control in our study. Overall, our molecular modeling data suggest that the p.R336C mutation induced conformational rearrangements at the functional core region, leading to loss of CBS activity.
CBS was reported to have several conformations, with the tetrameric and the higher multimeric forms: the correctly folded and active forms. Hence, any other form with misfolded conformation will force CBS to exist in an inactive state. In addition, it was previously reported that several CBS mutations cause a sharp decline in the resultant active tetramer compared with wild-type CBS, which was due to improper folding (Kozich et al., 2010) . Our findings in the yeast model showed the presence of tetrameric CBS protein in the pLR336C strain that resembled the one in the pLhCBS strain (Figure 2 ). However, the pLR336C strain failed to grow in the absence of exogenous cysteine, and CBS activity in the p.R336C-mutant strain was below the detection limit, which explains the inability of p.R336C CBS enzyme to support the growth of yeast and confirms our in silico and the mammalian cell model findings.
As previously reported (Singh & Kruger, 2009; Singh et al., 2007) , we showed that the p.I278T mutation leads to destabilization and degradation of CBS in yeast. However, this was not the case with the p.R336C mutation ( Figure 2B ). The different patterns of expression and migration between p.I278T and p.R336C in the denatured and native gels suggest that these two mutations may behave differently in our yeast model. Furthermore, in the native gel ( Figure 2B ), p.R336C protein seems to be stable and its migration pattern was similar to the hCBS; however, p.R336C enzyme activity was below detection limit (<5.0 nmol/mg/h) compared with the hCBS (109.7 nmol/mg/h). In the native gel of the HEK293T cells ( Figure 3D ), p.R336C was degraded, it fails to form tetramer, and its activity was below the detection limit.
The differences in the stability pattern of the p.R336C in yeast and mammalian cell models suggest that heterologous expression systems behave differently in modeling missense mutations. Although p.R336C
CBS protein may exist as a stable tetramer in p.R336C-mutant yeast strain ( Figure 2B ) or in p.R336C-HEK cells in response to betaine treatment (Figure 4 ), its enzyme activity was below the detection limit. This may be due to subtle conformational changes in the tertiary structure of the CBS caused by the p.R336C mutation that were not visible on or detected by native gels.
Our study is the first of its kind to use the knock-in technology to examine the effect of the p.R336C mutation in mammalian systems. The p.R336C mutation, which was successfully introduced in the HEK293T and HepG2 cells (Figure 3 ), had a more profound effect on CBS assembly in both cell lines than in the yeast model, whereby the properly assembled, functional tetrameric form of CBS was missing.
The qRT-PCR results showed that p.R336C mRNA expression in both cell lines ( Figure 3A ). We do understand that it might be hard to explain the reduction of mRNA levels harboring missense mutations. However, we constantly obtained these data, and this could be explained due changes in the stability of mRNA caused by p.R336C, which might lead to partial degradation of mRNA; however, testing for this is out of the scope of this work.
In this study, we chose the HepG2 cell line to express the p.R336C mutation, because CBS is mainly synthesized in the liver. However, the CBS activity in the wt-HepG2 was relatively low (9.8 mU/mg/h) compared with the wt-HEK293T (501.1 mU/mg/h; Figure 3 ). This is consistent with previous reports, which concluded that the CBS activity positively correlates with the rate of cell proliferation (Blank, Gajjar, Belyanin, & Polymenis, 2009 confluence and only about 15 mU/mg/h when cells were quiescent (Maclean et al., 2002) , compared with 9.8 mU/mg/h in the wt-HepG2 cells in this study. The small difference in the CBS activity between this and previous studies could be due to the variations in the used enzymatic assays (Kraus, 1987; Wang et al., 2004 ).
Casique and colleagues overexpressed two CBS mutants (p.T87N and p.D234N) in HEK293 cells using pcDNA4A/HisA (Casique, Kabil, Banerjee, Martinez, & De Lucca, 2013 with what previously reported by Kopecka et al. (2011) , who studied the effect of selected chaperones on 27 different CBS mutants. Of which, four mutants showed increased formation of CBS tetramers, without increase in the CBS activity (Kopecka et al., 2011) . In conclusion, our results suggest that the p.R336C mutation could be resistant to different chemical chaperones.
We have used different types of chaperone treatments at different concentrations in both yeast and tissue culture models other than the one shown in Figure 4 , such as DMSO, ethanol, heat, and even combinations of different treatments. All of these treatments were not able to rescue the conformation of the p.R336C CBS-mutant protein as betaine did (data not shown). However, we cannot rule out that other chaperone treatments that are available in the market could be able to rescue the p.R336C CBS conformation and activity defects. In addition, our study emphasizes the need for further investigation to improve chaperone treatment in order to benefit the Qatari patients.
One approach would be to use fibroblasts from Qatari CBS patients as a disease model and to test the potential effects of a wider range of chaperones on cells isolated from patients. This study is already under way.
Different treatment approaches, such as gene therapy or CBS enzyme replacement therapy (Bublil et al., 2016) , could be more promising than the chemical chaperone approach for treating Qatari patients. Other treatment options include the use of protein stabilizers or proteasome inhibitors. For instance, in a recent study, proteasome inhibitors were reported to rescue the phenotype in p.S466L-and p.I278T-mutant mice (Gupta et al., 2013) . In addition, bortezomib was reported to restore the growth and CBS activity in p.I278T-mutant yeast as well as in mice (Singh, Gupta, Honig, Kraus, & Kruger,
